What Have Caregivers Noticed About Cannabis Calming Dementia? 

As dementia progresses, behavioural symptoms such as agitation, anxiety, and sleep disturbance can be distressing for both patients and caregivers. Traditional medications, including antipsychotics and sedatives, can cause serious side effects, leading some families to explore whether cannabis-based medicines might offer a gentler alternative. 

Although no cannabis-based products for medicinal use (CBPMs) are currently licensed for dementia in the UK, emerging research and caregiver reports suggest that some patients may experience temporary relief from agitation or restlessness when cannabinoids are used under medical supervision. However, NICE and NHS England caution that evidence remains early and inconsistent, and cannabis should not replace standard dementia treatments (NICE NG144; NHS England, 2023). 

What Caregivers Report in Studies and Reviews 

Caregiver observations have become an important part of early research into cannabinoids for dementia-related behaviours. In a 2022 Frontiers in Aging Neuroscience study, care-home staff reported that residents treated with oral THC: CBD experienced less agitation and improved body rigidity. While the trial did not include a placebo group, caregivers noted “calmer social interactions” and reduced resistance to personal care routines. 

Similarly, in international observational reports such as Israel’s 2024 cohort study, caregivers described noticeable improvements in sleep and a reduction in night-time aggression among dementia patients receiving low-dose cannabinoids under supervision. They also highlighted the importance of consistent dosing, careful monitoring, and communication between family members and clinicians. 

Insights From Family Experiences and Clinical Trials 

Family caregivers interviewed in small-scale studies, such as those summarised by Health Canada (2023), have reported subtle but meaningful changes, less pacing, more settled evenings, and reduced anxiety during routine activities. Some also noticed that patients became more socially engaged after the introduction of CBD-dominant oils, although effects varied widely. 

In a 2025 University of Maryland trial, caregivers in palliative settings observed that oral THC: CBD blends helped reduce agitation and improved comfort near the end of life. The research team noted that caregivers’ impressions of calmness were valuable indicators, even when measurable cognitive changes were limited. 

However, not all reports have been positive. Some caregivers in older studies found that even small THC doses increased confusion or fatigue, highlighting the need for specialist oversight and cautious dosing. 

The Clinical Perspective: Why Evidence Still Matters 

According to the Medicines and Healthcare products Regulatory Agency (MHRA), cannabis remains an unlicensed medicine for dementia. This means any prescription carries additional clinical responsibility. Specialists on the GMC register may consider CBPMs only when conventional treatments have failed and when there is documented evidence of potential benefit. 

NICE and the BMJ (2024) both stress that caregiver feedback can inform research but cannot replace controlled evidence. While reported calmness or improved sleep may signal short-term benefit, it is unclear whether these improvements reflect direct neurological effects or simply relief from anxiety and pain. Rigorous trials are still needed to clarify these mechanisms and safety profiles. 

Ethical And Practical Considerations for Families 

Caregivers often face emotional and practical challenges when exploring cannabis-based options. Dementia can affect decision-making capacity, making informed consent complex. Ethical guidance from the Care Quality Commission (CQC) and GMC telemedicine standards emphasises that clinicians must ensure patients’ best interests and avoid remote prescribing without thorough evaluation. 

Caregivers should be encouraged to discuss any interest in medical cannabis with their GP or specialist. This allows clinicians to review potential drug interactions, assess symptom causes, and ensure safe monitoring, especially since most CBPMs used for dementia are unlicensed and prescribed privately. 

International Experiences Reflect Cautious Optimism 

Beyond the UK, caregiver reports from research programmes in Canada and Israel have informed broader understanding. The Health Canada 2023 report found that caregivers often described better sleep, reduced sundowning episodes, and calmer evenings in patients receiving low-dose cannabinoid oil. 

Meanwhile, Israel’s 2024 cohort reported measurable reductions in agitation scores and improved quality of life ratings from caregivers and nurses alike. Still, researchers caution that placebo effects, varying THC ratios, and caregiver expectations can influence these observations. 

Clinical Bottom Line 

• Caregivers frequently report calmer behaviour and better sleep in dementia patients using medical cannabis. 

• These improvements are subjective and not yet confirmed by large-scale clinical evidence. 

• NICE and NHS England do not approve CBPMs for dementia treatment. 

• Cannabis remains an unlicensed medicine, requiring GMC-registered specialist oversight. 

• Families should seek medical advice before considering any cannabis-based therapy. 

Role Of AlleviMed 

Educational platforms like AlleviMed help explain the UK’s regulated medical cannabis framework and eligibility standards. They offer factual information about prescribing pathways, safety requirements, and how unlicensed medicines are managed but do not issue prescriptions or offer treatment recommendations. For caregivers, AlleviMed provides clarity on what is legally and clinically appropriate when exploring cannabis-based options. 

Takeaway 

Many caregivers have noticed moments of calm and reduced agitation in loved ones with dementia after introducing cannabis-based medicines under supervision. Yet national regulators remain cautious, highlighting the need for stronger, placebo-controlled evidence. Until such data exist, cannabis use in dementia should only occur under specialist medical care, with close monitoring and open communication between families and healthcare professionals.